The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin

John W. Smith, Dan L. Longo, W. Gregory Alvord, John Edward Janik, William H. Sharfman, Barry L. Gause, Brendan D. Curti, Stephen P. Creekmore, Jon T. Holmlund, Robert G. Fenton, Mario Sznol, Langdon L. Miller, Masanao Shimizu, Joost J. Oppenheim, Shelby J. Fiem, Jean C. Hursey, Gerry C. Powers, Walter J. Urba

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Background: Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1α could ameliorate carboplatin-induced thrombocytopenia, we combined it with high-dose carboplatin in 43 patients with advanced neoplasms. Methods: High-dose carboplatin (800 mg per square meter of body-surface area) was administered alone to a control group. Subsequent patients were randomly assigned to receive the same dose of carboplatin with interleukin-1α, administered either before or after carboplatin. Interleukin-1α was given intravenously at a dose of 0.03, 0.1, or 0.3 μg per kilogram of body weight per day for five days. Results: Carboplatin alone consistently produced thrombocytopenia with a median nadir of 19,000 platelets per cubic millimeter and a median of 10 days with less than 100,000 platelets per cubic millimeter. All 15 patients receiving interleukin-1α before carboplatin had similar findings. In contrast, 5 of the 15 patients given one of the two higher doses of interleukin-1α after carboplatin had minimal thrombocytopenia (nadir, 91,000 to 332,000 platelets per cubic millimeter). In the 10 patients given 0.3 μg of interleukin-1α per kilogram after carboplatin treatment, the platelet count recovered to 100,000 per cubic millimeter significantly earlier than in either the control group (P = 0.002) or the patients who received interleukin-1α before carboplatin (P = 0.003), with the median times to recovery in the three groups being 16, 21, and 23 days, respectively. At the highest dose of interleukin-1α, toxicity was substantial (but reversible), requiring inpatient support for hypotension, supraventricular arrhythmias, and pulmonary-capillary leak. Conclusions: Interleukin-1α can accelerate the recovery of platelets after high-dose carboplatin therapy and may be clinically useful in preventing or treating thrombocytopenia induced by chemotherapy., Escalation of the dose of many antineoplastic drugs is limited by granulocytopenia and thrombocytopenia. Although colony-stimulating factors1,2 and the transplantation of bone marrow or peripheral-blood progenitor cells36 have had an effect on this problem, there are currently no strategies that permit repeated cycles of high-dose chemotherapy. Thrombocytopenia is not affected by granulocyte colony-stimulating factor1 or granulocyte-macrophage colony-stimulating factor2 and rapidly becomes dose-limiting after only moderate increments in chemotherapy despite the use of these factors. However, phase I studies of interleukin-1b7,8 and interleukin-1a9 have demonstrated that they cause platelet counts to become elevated one to two weeks after…

Original languageEnglish (US)
Pages (from-to)756-761
Number of pages6
JournalNew England Journal of Medicine
Volume328
Issue number11
DOIs
StatePublished - Mar 18 1993

Fingerprint

Carboplatin
Interleukin-1
Blood Platelets
Thrombocytopenia
Therapeutics
Drug Therapy
Platelet Count
Granulocytes
Control Groups
Agranulocytosis
Interleukins
Body Surface Area
Bone Marrow Transplantation
Interleukin-8
Antineoplastic Agents
Hypotension
Cardiac Arrhythmias
Inpatients
Neoplasms
Macrophages

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Smith, J. W., Longo, D. L., Alvord, W. G., Janik, J. E., Sharfman, W. H., Gause, B. L., ... Urba, W. J. (1993). The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin. New England Journal of Medicine, 328(11), 756-761. https://doi.org/10.1056/NEJM199303183281103

The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin. / Smith, John W.; Longo, Dan L.; Alvord, W. Gregory; Janik, John Edward; Sharfman, William H.; Gause, Barry L.; Curti, Brendan D.; Creekmore, Stephen P.; Holmlund, Jon T.; Fenton, Robert G.; Sznol, Mario; Miller, Langdon L.; Shimizu, Masanao; Oppenheim, Joost J.; Fiem, Shelby J.; Hursey, Jean C.; Powers, Gerry C.; Urba, Walter J.

In: New England Journal of Medicine, Vol. 328, No. 11, 18.03.1993, p. 756-761.

Research output: Contribution to journalArticle

Smith, JW, Longo, DL, Alvord, WG, Janik, JE, Sharfman, WH, Gause, BL, Curti, BD, Creekmore, SP, Holmlund, JT, Fenton, RG, Sznol, M, Miller, LL, Shimizu, M, Oppenheim, JJ, Fiem, SJ, Hursey, JC, Powers, GC & Urba, WJ 1993, 'The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin', New England Journal of Medicine, vol. 328, no. 11, pp. 756-761. https://doi.org/10.1056/NEJM199303183281103
Smith, John W. ; Longo, Dan L. ; Alvord, W. Gregory ; Janik, John Edward ; Sharfman, William H. ; Gause, Barry L. ; Curti, Brendan D. ; Creekmore, Stephen P. ; Holmlund, Jon T. ; Fenton, Robert G. ; Sznol, Mario ; Miller, Langdon L. ; Shimizu, Masanao ; Oppenheim, Joost J. ; Fiem, Shelby J. ; Hursey, Jean C. ; Powers, Gerry C. ; Urba, Walter J. / The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin. In: New England Journal of Medicine. 1993 ; Vol. 328, No. 11. pp. 756-761.
@article{9b756b1e1e0f4f66a4e91e199a847f57,
title = "The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin",
abstract = "Background: Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1α could ameliorate carboplatin-induced thrombocytopenia, we combined it with high-dose carboplatin in 43 patients with advanced neoplasms. Methods: High-dose carboplatin (800 mg per square meter of body-surface area) was administered alone to a control group. Subsequent patients were randomly assigned to receive the same dose of carboplatin with interleukin-1α, administered either before or after carboplatin. Interleukin-1α was given intravenously at a dose of 0.03, 0.1, or 0.3 μg per kilogram of body weight per day for five days. Results: Carboplatin alone consistently produced thrombocytopenia with a median nadir of 19,000 platelets per cubic millimeter and a median of 10 days with less than 100,000 platelets per cubic millimeter. All 15 patients receiving interleukin-1α before carboplatin had similar findings. In contrast, 5 of the 15 patients given one of the two higher doses of interleukin-1α after carboplatin had minimal thrombocytopenia (nadir, 91,000 to 332,000 platelets per cubic millimeter). In the 10 patients given 0.3 μg of interleukin-1α per kilogram after carboplatin treatment, the platelet count recovered to 100,000 per cubic millimeter significantly earlier than in either the control group (P = 0.002) or the patients who received interleukin-1α before carboplatin (P = 0.003), with the median times to recovery in the three groups being 16, 21, and 23 days, respectively. At the highest dose of interleukin-1α, toxicity was substantial (but reversible), requiring inpatient support for hypotension, supraventricular arrhythmias, and pulmonary-capillary leak. Conclusions: Interleukin-1α can accelerate the recovery of platelets after high-dose carboplatin therapy and may be clinically useful in preventing or treating thrombocytopenia induced by chemotherapy., Escalation of the dose of many antineoplastic drugs is limited by granulocytopenia and thrombocytopenia. Although colony-stimulating factors1,2 and the transplantation of bone marrow or peripheral-blood progenitor cells3–6 have had an effect on this problem, there are currently no strategies that permit repeated cycles of high-dose chemotherapy. Thrombocytopenia is not affected by granulocyte colony-stimulating factor1 or granulocyte-macrophage colony-stimulating factor2 and rapidly becomes dose-limiting after only moderate increments in chemotherapy despite the use of these factors. However, phase I studies of interleukin-1b7,8 and interleukin-1a9 have demonstrated that they cause platelet counts to become elevated one to two weeks after…",
author = "Smith, {John W.} and Longo, {Dan L.} and Alvord, {W. Gregory} and Janik, {John Edward} and Sharfman, {William H.} and Gause, {Barry L.} and Curti, {Brendan D.} and Creekmore, {Stephen P.} and Holmlund, {Jon T.} and Fenton, {Robert G.} and Mario Sznol and Miller, {Langdon L.} and Masanao Shimizu and Oppenheim, {Joost J.} and Fiem, {Shelby J.} and Hursey, {Jean C.} and Powers, {Gerry C.} and Urba, {Walter J.}",
year = "1993",
month = "3",
day = "18",
doi = "10.1056/NEJM199303183281103",
language = "English (US)",
volume = "328",
pages = "756--761",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin

AU - Smith, John W.

AU - Longo, Dan L.

AU - Alvord, W. Gregory

AU - Janik, John Edward

AU - Sharfman, William H.

AU - Gause, Barry L.

AU - Curti, Brendan D.

AU - Creekmore, Stephen P.

AU - Holmlund, Jon T.

AU - Fenton, Robert G.

AU - Sznol, Mario

AU - Miller, Langdon L.

AU - Shimizu, Masanao

AU - Oppenheim, Joost J.

AU - Fiem, Shelby J.

AU - Hursey, Jean C.

AU - Powers, Gerry C.

AU - Urba, Walter J.

PY - 1993/3/18

Y1 - 1993/3/18

N2 - Background: Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1α could ameliorate carboplatin-induced thrombocytopenia, we combined it with high-dose carboplatin in 43 patients with advanced neoplasms. Methods: High-dose carboplatin (800 mg per square meter of body-surface area) was administered alone to a control group. Subsequent patients were randomly assigned to receive the same dose of carboplatin with interleukin-1α, administered either before or after carboplatin. Interleukin-1α was given intravenously at a dose of 0.03, 0.1, or 0.3 μg per kilogram of body weight per day for five days. Results: Carboplatin alone consistently produced thrombocytopenia with a median nadir of 19,000 platelets per cubic millimeter and a median of 10 days with less than 100,000 platelets per cubic millimeter. All 15 patients receiving interleukin-1α before carboplatin had similar findings. In contrast, 5 of the 15 patients given one of the two higher doses of interleukin-1α after carboplatin had minimal thrombocytopenia (nadir, 91,000 to 332,000 platelets per cubic millimeter). In the 10 patients given 0.3 μg of interleukin-1α per kilogram after carboplatin treatment, the platelet count recovered to 100,000 per cubic millimeter significantly earlier than in either the control group (P = 0.002) or the patients who received interleukin-1α before carboplatin (P = 0.003), with the median times to recovery in the three groups being 16, 21, and 23 days, respectively. At the highest dose of interleukin-1α, toxicity was substantial (but reversible), requiring inpatient support for hypotension, supraventricular arrhythmias, and pulmonary-capillary leak. Conclusions: Interleukin-1α can accelerate the recovery of platelets after high-dose carboplatin therapy and may be clinically useful in preventing or treating thrombocytopenia induced by chemotherapy., Escalation of the dose of many antineoplastic drugs is limited by granulocytopenia and thrombocytopenia. Although colony-stimulating factors1,2 and the transplantation of bone marrow or peripheral-blood progenitor cells3–6 have had an effect on this problem, there are currently no strategies that permit repeated cycles of high-dose chemotherapy. Thrombocytopenia is not affected by granulocyte colony-stimulating factor1 or granulocyte-macrophage colony-stimulating factor2 and rapidly becomes dose-limiting after only moderate increments in chemotherapy despite the use of these factors. However, phase I studies of interleukin-1b7,8 and interleukin-1a9 have demonstrated that they cause platelet counts to become elevated one to two weeks after…

AB - Background: Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1α could ameliorate carboplatin-induced thrombocytopenia, we combined it with high-dose carboplatin in 43 patients with advanced neoplasms. Methods: High-dose carboplatin (800 mg per square meter of body-surface area) was administered alone to a control group. Subsequent patients were randomly assigned to receive the same dose of carboplatin with interleukin-1α, administered either before or after carboplatin. Interleukin-1α was given intravenously at a dose of 0.03, 0.1, or 0.3 μg per kilogram of body weight per day for five days. Results: Carboplatin alone consistently produced thrombocytopenia with a median nadir of 19,000 platelets per cubic millimeter and a median of 10 days with less than 100,000 platelets per cubic millimeter. All 15 patients receiving interleukin-1α before carboplatin had similar findings. In contrast, 5 of the 15 patients given one of the two higher doses of interleukin-1α after carboplatin had minimal thrombocytopenia (nadir, 91,000 to 332,000 platelets per cubic millimeter). In the 10 patients given 0.3 μg of interleukin-1α per kilogram after carboplatin treatment, the platelet count recovered to 100,000 per cubic millimeter significantly earlier than in either the control group (P = 0.002) or the patients who received interleukin-1α before carboplatin (P = 0.003), with the median times to recovery in the three groups being 16, 21, and 23 days, respectively. At the highest dose of interleukin-1α, toxicity was substantial (but reversible), requiring inpatient support for hypotension, supraventricular arrhythmias, and pulmonary-capillary leak. Conclusions: Interleukin-1α can accelerate the recovery of platelets after high-dose carboplatin therapy and may be clinically useful in preventing or treating thrombocytopenia induced by chemotherapy., Escalation of the dose of many antineoplastic drugs is limited by granulocytopenia and thrombocytopenia. Although colony-stimulating factors1,2 and the transplantation of bone marrow or peripheral-blood progenitor cells3–6 have had an effect on this problem, there are currently no strategies that permit repeated cycles of high-dose chemotherapy. Thrombocytopenia is not affected by granulocyte colony-stimulating factor1 or granulocyte-macrophage colony-stimulating factor2 and rapidly becomes dose-limiting after only moderate increments in chemotherapy despite the use of these factors. However, phase I studies of interleukin-1b7,8 and interleukin-1a9 have demonstrated that they cause platelet counts to become elevated one to two weeks after…

UR - http://www.scopus.com/inward/record.url?scp=0027469684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027469684&partnerID=8YFLogxK

U2 - 10.1056/NEJM199303183281103

DO - 10.1056/NEJM199303183281103

M3 - Article

C2 - 8437596

AN - SCOPUS:0027469684

VL - 328

SP - 756

EP - 761

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -